You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023238015
Dec 20239804
Jan 20247906
Feb 20246508
Mar 20244204
Apr 20244801
May 20243401
Jun 20248104
Jul 20245602
Aug 20244204
Sep 20244003
Oct 20243005
Nov 20244804
Dec 20243803
Jan 20253607
Feb 20251604
Apr 2025002
May 2025004
Jun 2025004
Total991085